TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer

Reuters
2025.11.17 13:05
portai
I'm PortAI, I can summarize articles.

TransCode Therapeutics Inc. has appointed Dr. Michel Janicot as Senior Development Officer. With over 35 years of experience in pharmaceutical research and oncology drug development, Dr. Janicot will support the company's lead oncology programs, TTX-MC138 and Seviprotimut-L, as they move toward late-stage clinical trials.

TransCode Therapeutics Inc. has appointed Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings over 35 years of experience in pharmaceutical research and oncology drug development. He will support research and development initiatives, particularly for the company’s lead oncology programs, TTX-MC138 and Seviprotimut-L, as they progress toward late-stage clinical trials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.